Cancer chemoprevention trials.
Clinical Trials Referral Resource is designed to serve as a ready reference for oncologists to help identify clinical trials that might be suitable for their patients. We hope it also will enhance accrual to clinical trials by informing practicing oncologists of ongoing protocols. Currently in the United States less than 10% of eligible adult patients are entered on clinical trials. The result is a delay in answering important therapeutic and scientific questions and disseminating therapeutic advances to the general oncology community. It should be emphasized that including a specific trial does not imply that it is more important than another trial. Among the criteria for selection are that the trial is addressing an important question and is not expected to close in the immediate future (less than 1 year), and that initial staging or laboratory tests required for patient eligibility are widely practiced and available. Information on other protocols can be accessed via Physician's Data Query (PDQ). We emphasize that this is an attempt to encourage referral of patients to these trials. We are specifically not soliciting additional members for the cooperative groups, nor are we suggesting how practicing oncologists should be treating patients not in a study. This month's installment of Clinical Trials Referral Resource is devoted to cancer chemoprevention trials. For patient entry information contact the person listed in each individual trial.
Brawley
O W
OW
National Cancer Institute.
Phillips
P H
PH
Cheson
B D
BD
D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D004311:Double-Blind Method; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000517:prevention & control
D015474:Isotretinoin; D001241:Aspirin